{"nct_id":"NCT05633654","title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)","status":"RECRUITING","status_verified_date":"2025-08","start_date":"2022-12-12","start_date_type":"ACTUAL","primary_completion_date":"2027-06","primary_completion_date_type":"ESTIMATED","completion_date":"2031-08","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["GILD"]}